(2-[(甲基氨基)磺酰基]苯基)硼酸 | 956283-09-3

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-[(甲基氨基)磺酰基]苯基)硼酸
• 中文别名: 2-(N-甲基磺酰氨基)苯硼酸
• 英文名称: (2-(N-methyl-sulfamoyl)-phenyl)boronic acid
• 英文别名: N-methylbenzenesulfonamide-2-boronic acid；(2-[(Methylamino)sulfonyl]phenyl)boronic acid；[2-(methylsulfamoyl)phenyl]boronic acid
• CAS: 956283-09-3
• 化学式: C₇H₁₀BNO₄S
• 分子量: 215.038
• InChiKey: AZXVSPOMIIRTDT-UHFFFAOYSA-N

物化性质

• 沸点：
  439.8±55.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.73
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  95
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2935009090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  -20°C，使用惰性气体保存

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (2-[(Methylamino)sulfonyl]phenyl)boronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: (2-[(Methylamino)sulfonyl]phenyl)boronic acid
CAS number: 956283-09-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H10BNO4S
Molecular weight: 215.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2-[(甲基氨基)磺酰基]苯基)硼酸 、 2-(5-bromo-8-methoxy-1,6-naphthyridin-7-yl)-5-(4-fluorobenzyl)-1,3,4-oxadiazole 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position

  摘要：

  The use of a 1,3,4-oxadiazole in combination with an 8-hydroxy-1,6-naphthyridine ring system has been shown to deliver potent enzyme and antiviral activity through inhibition of viral DNA integration. This report presents a detailed structure-activity investigation of the C5 position resulting in low nM potency for several analogs with an excellent therapeutic index. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.089
• 作为产物：
  描述：

  N-甲基苯磺酰胺 在 正丁基锂 、 硼酸三异丙酯 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 2.0h， 生成 (2-[(甲基氨基)磺酰基]苯基)硼酸
  参考文献：
  名称：

  Benzimidazole Modulators of VR1

  摘要：

  这项发明涉及到式（I）的化合物，以及包含这些化合物的药物组合物，以及使用它们的治疗方法。

  公开号：

  US20070259936A1

文献信息

• FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20150259357A1

  公开（公告）日：2015-09-17

  The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , R 2 , R 3 , R 3 ′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention

  本发明涉及式（I）的化合物，或其形式，其中环A，R1，R2，R3，R3'，L，W和V如本文所定义，可用作FLAP调节剂。该发明还涉及包含式（I）化合物的药物组合物。制备和使用式（I）化合物的方法也属于本发明的范围。
• Copper-mediated peptide arylation selective for the N-terminus
  作者：Mary K. Miller、Haopei Wang、Kengo Hanaya、Olivia Zhang、Alex Berlaga、Zachary T. Ball

  DOI：10.1039/d0sc02933e

  日期：——

  paradigms exist for reactivity and selectivity in arylation of amine groups. This communication describes the utilization of boronic acid reagents bearing certain o-electron withdrawing groups for copper-mediated amine arylation of the N-terminus under mild conditions and primarily aqueous solvent. The method adds to the toolkit of boronic acid reagents for polypeptide modification under mild conditions

  多肽对化学方法提出了显着的选择性挑战。氨基在多肽结构中无处不在，但胺基芳基化的反应性和选择性的范例很少。该通讯描述了在温和条件和主要水溶剂下，利用带有某些邻电子吸电子基团的硼酸试剂进行铜介导的N末端胺芳基化。该方法添加到硼酸试剂工具包中，用于在温和条件下在水中进行多肽修饰，在赖氨酸侧链存在的情况下显示出对 N 末端的完全选择性。
• Boronic Acid Pairs for Sequential Bioconjugation
  作者：Mary K. Miller、Michael J. Swierczynski、Yuxuan Ding、Zachary T. Ball

  DOI：10.1021/acs.orglett.1c01624

  日期：2021.7.16

  Boronic acids can play diverse roles when applied in biological environments, and employing boronic acid structures in tandem could provide new tools for multifunctional probes. This Letter describes a pair of boronic acid functional groups, 2-nitro-arylboronic acid (NAB) and (E)-alkenylboronic acid (EAB), that enable sequential cross-coupling through stepwise nickel- and copper-catalyzed processes

  硼酸在生物环境中可以发挥多种作用，串联使用硼酸结构可以为多功能探针提供新的工具。这封信描述了一对硼酸官能团，2-硝基-芳基硼酸 (NAB) 和 ( E )-烯基硼酸 (EAB)，它们能够通过逐步的镍和铜催化过程进行顺序交叉偶联。NAB 基团的选择性偶联能够制备钉合肽、蛋白质-蛋白质偶联物和其他生物偶联物。
• Flap modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US09079866B2

  公开（公告）日：2015-07-14

  The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, R2, R3, R3′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

  本发明涉及公式(I)的化合物或其形式，其中环A、R1、R2、R3、R3′、L、W和V的定义如本文所述，可用于FLAP调节剂。本发明还涉及包含公式(I)化合物的药物组成物。制备和使用公式(I)化合物的方法也属于本发明的范围。
• Direct formation and site-selective elaboration of methionine sulfoximine in polypeptides
  作者：Yuxuan Ding、Simon S. Pedersen、Alex Lin、Ruoyu Qian、Zachary T. Ball

  DOI：10.1039/d2sc04220g

  日期：——

  sulfoximine (MSO) and its derivatives are well studied, structures with methionine sulfoximine residues within complex polypeptides have been generally inaccessible. This paper describes a straightforward means of late-stage one-step oxidation of methionine residues within polypeptides to afford NH-sulfoximines. We also present chemoselective subsequent elaboration, most notably by copper(II)-mediated N–H cross-coupling

  亚砜亚胺是药物和生物化学的新兴成分，部分原因在于它们在选择性抑制酰胺形成酶（例如 γ-谷氨酰半胱氨酸合成酶）方面的功效。虽然小分子亚砜亚胺如甲硫氨酸亚砜亚胺 (MSO) 及其衍生物得到了很好的研究，但复杂多肽中具有甲硫氨酸亚砜亚胺残基的结构通常是不可接近的。本文描述了一种直接的方法，用于后期一步氧化多肽中的甲硫氨酸残基以提供 NH-亚砜亚胺。我们还介绍了化学选择性后续阐述，最显着的是铜 ( II)-介导的甲硫氨酸亚砜亚胺残基与芳基硼酸试剂的 N-H 交叉偶联。这一发展可作为将多种亚砜亚胺结构整合到天然多肽中的策略，并将甲硫氨酸亚砜亚胺残基鉴定为生物正交、化学选择性生物偶联的新位点。